We have also recently identified SSX2 p103–111 as an SSX2 epitope using HLA-A2 transgenic mice immunized with a genetic vaccine encoding SSX2, and further identified that p103–111-specific CTL can lyse HLA-A2-expressing prostate tumor cells (Smith, manuscript submitted). This evidence concerns the gene SSX2 and prostate neoplasm.